|
In vitro antibacterial activity was determined as inhibitory concentration causing 50% DNA-gyrase supercoiling inhibition (SCI)
|
Escherichia coli
|
83.3
ug.mL-1
|
|
|
Inhibitory effect on the oxidative degradation of membrane lipids (lipid peroxidation assay) in microsomes of rat.
|
Rattus norvegicus
|
200.0
nM
|
|
|
Inhibition of glycogen synthase kinase 3
|
None
|
420.0
nM
|
|
|
Inhibition of cyclin-dependent kinase 1/cyclinB
|
None
|
790.0
nM
|
|
|
Inhibition of Cyclin-dependent kinase 5-p25nck5a
|
None
|
570.0
nM
|
|
|
Inhibition of human cyclin-dependent kinase 6 complex with a virus-encoded cyclin from herpesvirus saimiri (Vcyclin)
|
Homo sapiens
|
850.0
nM
|
|
|
Inhibition of 12-hLO
|
None
|
950.0
nM
|
|
|
Inhibition of calf thymus DNA topoisomerase 1 catalytic domain-mediated supercoiled Escherichia coli pUC8 DNA relaxation after 30 mins by agarose gel electrophoresis
|
Bos taurus
|
20.6
ug.mL-1
|
|
|
Inhibition of human DNA topoisomerase 2 catalytic domain-mediated knotted bacteriophage P4Virl dell0 DNA unknotting by agarose gel electrophoresis
|
Homo sapiens
|
8.2
ug.mL-1
|
|
|
Inhibition of rat liver mitochondrial ATPase assessed per mg of protein
|
Rattus norvegicus
|
480.0
nM
|
|
|
Inhibition of beef heart mitochondrial NADH oxidase assessed per mg of protein
|
Bos taurus
|
15.0
nM
|
|
|
Inhibition of beef heart mitochondrial succinoxidase assessed per mg of protein
|
Bos taurus
|
45.0
nM
|
|
|
Inhibition of bovine thymus p56LCK-catalyzed phosphorylation of angiotensin 1 by SDS-PAGE
|
Bos taurus
|
4.0
ug.mL-1
|
|
|
Inhibition of Saccharomyces cerevisiae fatty acid synthase
|
Saccharomyces cerevisiae
|
50.0
ug.mL-1
|
|
|
Antifungal activity against Candida albicans ATCC 90028
|
Candida albicans
|
50.0
ug.mL-1
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 90113
|
Cryptococcus neoformans
|
50.0
ug.mL-1
|
|
|
Inhibition of p56 lck
|
None
|
4.0
ug.mL-1
|
|
|
Inhibition of CK2
|
None
|
350.0
nM
|
|
|
Inhibition of human salivary alpha-amylase
|
Homo sapiens
|
85.6
%
|
|
|
Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication at 50 uM after 72 hrs by EGFP assay
|
Hepatitis C virus JFH-1
|
26.4
%
|
|
|
Inhibition of electric eel AChE at 2 mg/ml by Ellman's method
|
Electrophorus electricus
|
27.48
%
|
|
|
Inhibition of horse BChE at 2 mg/ml by Ellman's method
|
Equus caballus
|
2.06
%
|
|
|
Inhibition of Homo sapiens (human) cyclin-dependent kinase 6
|
Homo sapiens
|
850.0
nM
|
|
|
Antioxidant activity assessed as inhibition of DPPH radical production at 33 uM after 5 min by spectrophotometric analysis
|
None
|
79.0
%
|
|
|
Antiamoebic activity against Entamoeba histolytica
|
Entamoeba histolytica
|
189.01
ug.mL-1
|
|
|
Inhibition of AChE (unknown origin)
|
Homo sapiens
|
12.0
nM
|
|
|
Inhibition of CK2 (unknown origin)
|
Homo sapiens
|
350.0
nM
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
56.32
%
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
108.53
%
|
|
|
Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins
|
None
|
9.26
ug.mL-1
|
|
|
Antiviral activity against dengue virus 2 infected in african green monkey Vero cells assessed as reduction in viral replication dosed after adsorption with 200 FFU of virus for 1 hour by foci forming unit reduction assay
|
Dengue virus 2
|
55.0
ug.mL-1
|
|
|
Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by alamar blue staining based fluorescence analysis
|
Trypanosoma brucei rhodesiense
|
3.3
ug.mL-1
|
|
|
Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis
|
Rattus norvegicus
|
38.5
ug.mL-1
|
|
|
Antileishmanial activity against Leishmania donovani MHOM/ET/67/L82 after 72 hrs by Alamar blue dye based fluorescence analysis
|
Leishmania donovani
|
0.6
ug.mL-1
|
|
|
Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method
|
Trypanosoma cruzi
|
30.0
ug.mL-1
|
|
|
Inhibition of CK2 (unknown origin)
|
Homo sapiens
|
170.0
nM
|
|
|
In vivo inhibition of MAOA in ICR mouse brain at 20 mg/kg administered via oral gavage using kynuramine dihydrobromide as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins in presence of MAOB inhibitor deprenyl by fluorescence spectrometric method
|
Mus musculus
|
14.7
%
|
|
|
Inhibition of sucrose loaded POPC/POPE/POPS/PtdIns(3,4,5)P3 (59:20:20:1) liposome binding to eGFP-fused PDK1 PH domain (unknown origin) expressed in Escherichia coli BL21 at 20 uM after 10 mins by fluorescence spectrophotometry based pull down assay relative to control
|
Homo sapiens
|
37.59
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
-1.83
%
|
|
|
Inhibition of CK2alpha (unknown origin)
|
Homo sapiens
|
350.0
nM
|
|
|
Inhibition of human recombinant CK2 expressed in Escherichia coli using RRRADDSDDDDD as substrate after 10 mins in presence of [gamma-32P]ATP
|
Homo sapiens
|
350.0
nM
|
|
|
Inhibition of PKC in rat brain homogenate at 50 uM using FKKSFKL-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins in presence of [gamma-32P]ATP by liquid scintillation counting analysis relative to control
|
Rattus norvegicus
|
85.0
%
|
|
|
Inhibition of Trypanosoma brucei PTR1 at 50 uM using H2B as substrate incubated for 10 mins followed by addition of NADPH measured for 10 to 50 mins
|
Trypanosoma brucei
|
53.0
%
|
|
|
Inhibition of Leishmania mexicana DHFR at 50 uM using folic aid as substrate by spectrophotometric analysis
|
Leishmania mexicana
|
25.0
%
|
|
|
Inhibition of Trypanosoma brucei DHFR at 50 uM using folic aid as substrate by spectrophotometric analysis
|
Trypanosoma brucei
|
25.0
%
|
|
|
Inhibition of human DHFR at 50 uM using folic aid as substrate by spectrophotometric analysis
|
Homo sapiens
|
30.0
%
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
-7.013
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.12
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.12
%
|
|
|
Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoic acid binding to Influenza A virus (A/California/07/2009(H1N1)) N-terminal GST-tagged polymerase acidic subunit N-terminal domain expressed in Escherichia coli BL21 (DE3) RIL cells measured after 120 mins by Alphascreen assay
|
Influenza A virus (A/California/07/2009(H1N1))
|
960.0
nM
|
|
|
Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL complex formation at 10 uM incubated for 15 mins in presence of cardiolipin by Trp-59 fluorescence assay relative to control
|
Homo sapiens
|
85.0
%
|
|
|
Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL peroxidase activity at 10 uM up to 20 mins in presence of cardiolipin by Amplex red staining based fluorescence assay relative to control
|
Homo sapiens
|
81.0
%
|
|
|
Inhibition of cytochrome c (unknown origin) assessed as reduction reduction of cyt c from its ferric state to ferrous state at 10 uM incubated for 20 mins in presence of cardiolipin by UV-vis Spectrophotometric assay relative to control
|
Homo sapiens
|
73.0
%
|
|
